Abstract
The value of intravenous lignocaine ('Xylocaine') in the management of arrhythmias after acute myocardial infarction has been assessed. Of twenty-seven patients with frequent ventricular extrasystoles, adequate suppression was achieved in twenty-four using a continuous intravenous infusion of lignocaine 1-2 mg. per minute. Ventricular tachycardia was terminated in eleven patients by a single intravenous injection of 1-2 mg. per kg. body-weight, without resort to D.C. cardioversion. Lignocaine was of little value in the management of supraventricular arrhythmias. Hæmodynamic studies in eight patients have shown no deleterious side-effects after intravenous lignocaine in this dosage. It is suggested that lignocaine is the anti-arrhythmic drug of choice in the management of ventricular arrhythmias after acute myocardial infarction.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
